A Pilot Study of Image Guided Prostate and Pelvic Nodal Irradiation With Intensity Modulated Radiation Therapy (IMRT) in Prostate Cancer
Treatment Plan
Arm/Group Label
Arm/Group Type
Arm/Group Description
Not Provided
Intervention(s)
radiation therapy,
Patient eligibility
DISEASE CHARACTERISTICS:
- Histologically confirmed adenocarcinoma of the prostate
- Risk of lymph node metastasis >= 10% OR biopsy-proven positive lymph nodes
- No metastatic disease beyond the pelvis
- Tumor visible on MRI
PATIENT CHARACTERISTICS:
- ECOG performance status 0-2
- No bleeding disorders
- PT and PTT < 1.5 times upper limit of normal
- Platelet count > 50,000/mm^3
- No artificial heart valve
- Weight <= 136 kg
- No allergy to magnetic resonance contrast agent
- No pacemakers, cerebral aneurysm clips, shrapnel injury, or implantable electronic
devices
- No pre-existing or active prostatitis or proctitis
- No medical conditions, based on the opinion of the principal investigator, that would
preclude study treatment
- No cognitively impaired patients who cannot give informed consent
PRIOR CONCURRENT THERAPY:
- No prior surgery, radiotherapy, or chemotherapy for this cancer except for
neoadjuvant hormone therapy for up to 4 months
- Must receive neoadjuvant, concurrent, and adjuvant hormone therapy
- Must receive a nonsteroidal anti-androgen, such as flutamide, for approximately
6-8 weeks prior to starting radiotherapy
- Must receive a gonadotropin releasing-hormone agonist for concurrent and
adjuvant therapy
- Adjuvant therapy continues for 3 years or indefinitely
- No other concurrent surgery except standard biopsy
- No concurrent cytotoxic chemotherapy
For detailed patient eligibility criteria for this clinical trial, please click here to show/hide
